Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock Competitors & Peer Comparison

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while TAK trades at $17.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas TAK's P/E ratio is 12.52. In terms of profitability, RGC's ROE is -2.32%, compared to TAK's ROE of +0.02%. Regarding short-term risk, RGC is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for RGC.Check TAK's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while HLN trades at $9.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas HLN's P/E ratio is 18.28. In terms of profitability, RGC's ROE is -2.32%, compared to HLN's ROE of +0.17%. Regarding short-term risk, RGC is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for RGC.Check HLN's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while TEVA trades at $37.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas TEVA's P/E ratio is 12.54. In terms of profitability, RGC's ROE is -2.32%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, RGC is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for RGC.Check TEVA's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while VTRS trades at $16.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas VTRS's P/E ratio is 6.39. In terms of profitability, RGC's ROE is -2.32%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, RGC is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for RGC.Check VTRS's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ITCI's P/E ratio is -180.64. In terms of profitability, RGC's ROE is -2.32%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, RGC is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for RGC.Check ITCI's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas CTLT's P/E ratio is -27.84. In terms of profitability, RGC's ROE is -2.32%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, RGC is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for RGC.Check CTLT's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ELAN trades at $22.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ELAN's P/E ratio is 20.91. In terms of profitability, RGC's ROE is -2.32%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, RGC is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for RGC.Check ELAN's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while RDY trades at $12.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas RDY's P/E ratio is 20.30. In terms of profitability, RGC's ROE is -2.32%, compared to RDY's ROE of +0.09%. Regarding short-term risk, RGC is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for RGC.Check RDY's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while LNTH trades at $100.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas LNTH's P/E ratio is 16.93. In terms of profitability, RGC's ROE is -2.32%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, RGC is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for RGC.Check LNTH's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while AMRX trades at $17.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas AMRX's P/E ratio is 19.62. In terms of profitability, RGC's ROE is -2.32%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, RGC is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for RGC.Check AMRX's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while INDV trades at $38.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas INDV's P/E ratio is 10.61. In terms of profitability, RGC's ROE is -2.32%, compared to INDV's ROE of -2.16%. Regarding short-term risk, RGC is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for RGC.Check INDV's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while SUPN trades at $47.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas SUPN's P/E ratio is 15.64. In terms of profitability, RGC's ROE is -2.32%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, RGC is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for RGC.Check SUPN's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while BHC trades at $6.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas BHC's P/E ratio is 1.58. In terms of profitability, RGC's ROE is -2.32%, compared to BHC's ROE of +0.89%. Regarding short-term risk, RGC is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for RGC.Check BHC's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas DCPH's P/E ratio is -11.58. In terms of profitability, RGC's ROE is -2.32%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, RGC is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for RGC.Check DCPH's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while HCM trades at $12.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas HCM's P/E ratio is 4.59. In terms of profitability, RGC's ROE is -2.32%, compared to HCM's ROE of +0.01%. Regarding short-term risk, RGC is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for RGC.Check HCM's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, RGC's ROE is -2.32%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, RGC is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for RGC.Check AVDL's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas EMBCV's P/E ratio is N/A. In terms of profitability, RGC's ROE is -2.32%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, RGC is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for RGC.Check EMBCV's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas DVAX's P/E ratio is -41.89. In terms of profitability, RGC's ROE is -2.32%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, RGC is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for RGC.Check DVAX's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while PRGO trades at $12.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas PRGO's P/E ratio is 5.07. In terms of profitability, RGC's ROE is -2.32%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, RGC is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for RGC.Check PRGO's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ANIP trades at $75.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ANIP's P/E ratio is 9.14. In terms of profitability, RGC's ROE is -2.32%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, RGC is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for RGC.Check ANIP's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas TARO's P/E ratio is 30.05. In terms of profitability, RGC's ROE is -2.32%, compared to TARO's ROE of +0.03%. Regarding short-term risk, RGC is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for RGC.Check TARO's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while HROW trades at $39.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas HROW's P/E ratio is 437.33. In terms of profitability, RGC's ROE is -2.32%, compared to HROW's ROE of -1.04%. Regarding short-term risk, RGC is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for RGC.Check HROW's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while PAHC trades at $34.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas PAHC's P/E ratio is 11.54. In terms of profitability, RGC's ROE is -2.32%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, RGC is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for RGC.Check PAHC's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ALVO trades at $3.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ALVO's P/E ratio is -11.79. In terms of profitability, RGC's ROE is -2.32%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, RGC is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for RGC.Check ALVO's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while CRON trades at $3.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas CRON's P/E ratio is 30.10. In terms of profitability, RGC's ROE is -2.32%, compared to CRON's ROE of +0.06%. Regarding short-term risk, RGC is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for RGC.Check CRON's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ETON trades at $42.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ETON's P/E ratio is -594.00. In terms of profitability, RGC's ROE is -2.32%, compared to ETON's ROE of -0.06%. Regarding short-term risk, RGC is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for RGC.Check ETON's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while PCRX trades at $23.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas PCRX's P/E ratio is 9.12. In terms of profitability, RGC's ROE is -2.32%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, RGC is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for RGC.Check PCRX's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas PETQ's P/E ratio is 83.73. In terms of profitability, RGC's ROE is -2.32%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, RGC is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for RGC.Check PETQ's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while AMPH trades at $20.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas AMPH's P/E ratio is 6.82. In terms of profitability, RGC's ROE is -2.32%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, RGC is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for RGC.Check AMPH's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while COLL trades at $28.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas COLL's P/E ratio is 3.26. In terms of profitability, RGC's ROE is -2.32%, compared to COLL's ROE of +0.16%. Regarding short-term risk, RGC is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for RGC.Check COLL's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, EVO has a market cap of 778M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while EVO trades at $2.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas EVO's P/E ratio is -3.09. In terms of profitability, RGC's ROE is -2.32%, compared to EVO's ROE of -0.24%. Regarding short-term risk, RGC is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for RGC.Check EVO's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while IRWD trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas IRWD's P/E ratio is 5.54. In terms of profitability, RGC's ROE is -2.32%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, RGC is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for RGC.Check IRWD's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas BDSI's P/E ratio is 6.82. In terms of profitability, RGC's ROE is -2.32%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, RGC is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for RGC.Check BDSI's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while EOLS trades at $8.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas EOLS's P/E ratio is -25.71. In terms of profitability, RGC's ROE is -2.32%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, RGC is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for RGC.Check EOLS's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while AQST trades at $4.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas AQST's P/E ratio is -6.93. In terms of profitability, RGC's ROE is -2.32%, compared to AQST's ROE of +2.44%. Regarding short-term risk, RGC is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for RGC.Check AQST's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while TLRY trades at $4.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas TLRY's P/E ratio is -4.32. In terms of profitability, RGC's ROE is -2.32%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, RGC is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for RGC.Check TLRY's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while CGC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas CGC's P/E ratio is -0.62. In terms of profitability, RGC's ROE is -2.32%, compared to CGC's ROE of -0.33%. Regarding short-term risk, RGC is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for RGC.Check CGC's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while KMDA trades at $7.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas KMDA's P/E ratio is 19.66. In terms of profitability, RGC's ROE is -2.32%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, RGC is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for RGC.Check KMDA's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while TKNO trades at $7.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas TKNO's P/E ratio is -23.84. In terms of profitability, RGC's ROE is -2.32%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, RGC is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for RGC.Check TKNO's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ALIM's P/E ratio is 5.28. In terms of profitability, RGC's ROE is -2.32%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, RGC is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for RGC.Check ALIM's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while EMBC trades at $5.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas EMBC's P/E ratio is 1.83. In terms of profitability, RGC's ROE is -2.32%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, RGC is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for RGC.Check EMBC's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas LNDC's P/E ratio is -4.04. In terms of profitability, RGC's ROE is -2.32%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, RGC is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for RGC.Check LNDC's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ACB trades at $3.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ACB's P/E ratio is -7.80. In terms of profitability, RGC's ROE is -2.32%, compared to ACB's ROE of -0.21%. Regarding short-term risk, RGC is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for RGC.Check ACB's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ORGO trades at $1.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ORGO's P/E ratio is 60.33. In terms of profitability, RGC's ROE is -2.32%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, RGC is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for RGC.Check ORGO's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas TYHT's P/E ratio is -1.61. In terms of profitability, RGC's ROE is -2.32%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, RGC is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for RGC.Check TYHT's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while SIGA trades at $2.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas SIGA's P/E ratio is 10.63. In terms of profitability, RGC's ROE is -2.32%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, RGC is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for RGC.Check SIGA's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while OGI trades at $1.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas OGI's P/E ratio is -4.96. In terms of profitability, RGC's ROE is -2.32%, compared to OGI's ROE of -0.07%. Regarding short-term risk, RGC is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for RGC.Check OGI's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while LFCR trades at $4.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas LFCR's P/E ratio is -4.46. In terms of profitability, RGC's ROE is -2.32%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, RGC is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for RGC.Check LFCR's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas REPH's P/E ratio is -8.04. In terms of profitability, RGC's ROE is -2.32%, compared to REPH's ROE of -0.22%. Regarding short-term risk, RGC is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for RGC.Check REPH's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while DERM trades at $6.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas DERM's P/E ratio is -17.38. In terms of profitability, RGC's ROE is -2.32%, compared to DERM's ROE of -0.36%. Regarding short-term risk, RGC is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for RGC.Check DERM's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while CRDL trades at $1.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas CRDL's P/E ratio is -5.41. In terms of profitability, RGC's ROE is -2.32%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, RGC is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for RGC.Check CRDL's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas THTX's P/E ratio is -28.83. In terms of profitability, RGC's ROE is -2.32%, compared to THTX's ROE of +0.17%. Regarding short-term risk, RGC is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for RGC.Check THTX's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ASRT's P/E ratio is -7.10. In terms of profitability, RGC's ROE is -2.32%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, RGC is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for RGC.Check ASRT's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while CPIX trades at $7.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas CPIX's P/E ratio is -19.90. In terms of profitability, RGC's ROE is -2.32%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, RGC is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for RGC.Check CPIX's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas SCTL's P/E ratio is -7.86. In terms of profitability, RGC's ROE is -2.32%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, RGC is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for RGC.Check SCTL's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while BGM trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas BGM's P/E ratio is -1.01. In terms of profitability, RGC's ROE is -2.32%, compared to BGM's ROE of -0.07%. Regarding short-term risk, RGC is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for RGC.Check BGM's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas PROC's P/E ratio is 1.53. In terms of profitability, RGC's ROE is -2.32%, compared to PROC's ROE of -2.22%. Regarding short-term risk, RGC is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for RGC.Check PROC's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas OPTN's P/E ratio is -4.42. In terms of profitability, RGC's ROE is -2.32%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, RGC is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for RGC.Check OPTN's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ZOM's P/E ratio is -1.62. In terms of profitability, RGC's ROE is -2.32%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, RGC is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for RGC.Check ZOM's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas GRVI's P/E ratio is 26.05. In terms of profitability, RGC's ROE is -2.32%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, RGC is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for RGC.Check GRVI's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ZYBT trades at $1.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, RGC's ROE is -2.32%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, RGC is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for RGC.Check ZYBT's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while TLPH trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas TLPH's P/E ratio is -4.52. In terms of profitability, RGC's ROE is -2.32%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, RGC is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for RGC.Check TLPH's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, RGC's ROE is -2.32%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, RGC is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for RGC.Check ZYNE's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas SSIC's P/E ratio is 11.93. In terms of profitability, RGC's ROE is -2.32%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, RGC is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for RGC.Check SSIC's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas VLNS's P/E ratio is -1.03. In terms of profitability, RGC's ROE is -2.32%, compared to VLNS's ROE of N/A. Regarding short-term risk, RGC is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for RGC.Check VLNS's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas DRRX's P/E ratio is -4.44. In terms of profitability, RGC's ROE is -2.32%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, RGC is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for RGC.Check DRRX's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while INCR trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas INCR's P/E ratio is -2.23. In terms of profitability, RGC's ROE is -2.32%, compared to INCR's ROE of -0.09%. Regarding short-term risk, RGC is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for RGC.Check INCR's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas JUPW's P/E ratio is -2.41. In terms of profitability, RGC's ROE is -2.32%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, RGC is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for RGC.Check JUPW's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while CPHI trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas CPHI's P/E ratio is -1.72. In terms of profitability, RGC's ROE is -2.32%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, RGC is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for RGC.Check CPHI's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas QLI's P/E ratio is -4.92. In terms of profitability, RGC's ROE is -2.32%, compared to QLI's ROE of -0.16%. Regarding short-term risk, RGC is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for RGC.Check QLI's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas HEXO's P/E ratio is -0.26. In terms of profitability, RGC's ROE is -2.32%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, RGC is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for RGC.Check HEXO's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while RMTI trades at $7.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas RMTI's P/E ratio is -7.42. In terms of profitability, RGC's ROE is -2.32%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, RGC is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for RGC.Check RMTI's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while AYTU trades at $2.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas AYTU's P/E ratio is -1.23. In terms of profitability, RGC's ROE is -2.32%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, RGC is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for RGC.Check AYTU's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while TXMD trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas TXMD's P/E ratio is 105.96. In terms of profitability, RGC's ROE is -2.32%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, RGC is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for RGC.Check TXMD's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas CYTH's P/E ratio is -0.80. In terms of profitability, RGC's ROE is -2.32%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, RGC is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for RGC.Check CYTH's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas EVOK's P/E ratio is -7.97. In terms of profitability, RGC's ROE is -2.32%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, RGC is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for RGC.Check EVOK's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while OPTH trades at $4.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas OPTH's P/E ratio is -17.38. In terms of profitability, RGC's ROE is -2.32%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, RGC is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for RGC.Check OPTH's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ACRX's P/E ratio is -0.31. In terms of profitability, RGC's ROE is -2.32%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, RGC is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for RGC.Check ACRX's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while BFRIW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, RGC's ROE is -2.32%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, RGC is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for RGC.Check BFRIW's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while COSM trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas COSM's P/E ratio is -0.29. In terms of profitability, RGC's ROE is -2.32%, compared to COSM's ROE of -0.96%. Regarding short-term risk, RGC is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for RGC.Check COSM's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas AGRX's P/E ratio is -0.89. In terms of profitability, RGC's ROE is -2.32%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, RGC is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for RGC.Check AGRX's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas NLTX's P/E ratio is -0.28. In terms of profitability, RGC's ROE is -2.32%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, RGC is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for RGC.Check NLTX's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas LCI's P/E ratio is -0.04. In terms of profitability, RGC's ROE is -2.32%, compared to LCI's ROE of +1.66%. Regarding short-term risk, RGC is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for RGC.Check LCI's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ADMP's P/E ratio is -0.08. In terms of profitability, RGC's ROE is -2.32%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, RGC is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for RGC.Check ADMP's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while YCBD trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas YCBD's P/E ratio is -1.49. In terms of profitability, RGC's ROE is -2.32%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, RGC is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for RGC.Check YCBD's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while GELS trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas GELS's P/E ratio is -1.14. In terms of profitability, RGC's ROE is -2.32%, compared to GELS's ROE of -0.25%. Regarding short-term risk, RGC is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for RGC.Check GELS's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas MNK's P/E ratio is -0.44. In terms of profitability, RGC's ROE is -2.32%, compared to MNK's ROE of -0.36%. Regarding short-term risk, RGC is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for RGC.Check MNK's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas FLGC's P/E ratio is -0.19. In terms of profitability, RGC's ROE is -2.32%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, RGC is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for RGC.Check FLGC's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while UPC trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas UPC's P/E ratio is -0.75. In terms of profitability, RGC's ROE is -2.32%, compared to UPC's ROE of -0.03%. Regarding short-term risk, RGC is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for RGC.Check UPC's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while SBFM trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas SBFM's P/E ratio is -0.20. In terms of profitability, RGC's ROE is -2.32%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, RGC is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for RGC.Check SBFM's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas PLXP's P/E ratio is -0.22. In terms of profitability, RGC's ROE is -2.32%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, RGC is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for RGC.Check PLXP's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while SHPH trades at $4.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas SHPH's P/E ratio is -0.20. In terms of profitability, RGC's ROE is -2.32%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, RGC is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for RGC.Check SHPH's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas ATNX's P/E ratio is -0.02. In terms of profitability, RGC's ROE is -2.32%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, RGC is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for RGC.Check ATNX's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while SNOA trades at $1.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas SNOA's P/E ratio is -1.16. In terms of profitability, RGC's ROE is -2.32%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, RGC is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for RGC.Check SNOA's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while PROCW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas PROCW's P/E ratio is N/A. In terms of profitability, RGC's ROE is -2.32%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, RGC is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for RGC.Check PROCW's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while RDHL trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas RDHL's P/E ratio is 0.12. In terms of profitability, RGC's ROE is -2.32%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, RGC is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for RGC.Check RDHL's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while SXTC trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas SXTC's P/E ratio is 1.18. In terms of profitability, RGC's ROE is -2.32%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, RGC is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for RGC.Check SXTC's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while YCBD-PA trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, RGC's ROE is -2.32%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, RGC is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for RGC.Check YCBD-PA's competition here

Regencell Bioscience Holdings Limited (NASDAQ: RGC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RGC stands at 2.5B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, RGC is priced at $5.14 on the NASDAQ, while CYTHW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RGC currently has a P/E ratio of -356.34, whereas CYTHW's P/E ratio is N/A. In terms of profitability, RGC's ROE is -2.32%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, RGC is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for RGC.Check CYTHW's competition here